Hosted by Cardiff University's School of Medicine

 

The covid pandemic put the NHS under unprecedented stress. Was it appropriate to attempt to conduct a randomized trial under such circumstances, and can such a trial provide any lessons for trials in non-pandemic situations?

Please register at Eventbrite for your free place

Richard Haynes is Professor of Renal Medicine and Clinical Trials in the Nuffield Department of Population Health at Oxford University. After studying preclinical medicine at Cambridge University and clinical medicine at Oxford University, Richard trained in nephrology in the Oxford Deanery. During his training he spent some time at the Clinical Trial Service Unit at Oxford University to learn how to run clinical trials. He has led trials in nephrology including being co-principal investigator of the EMPA-KIDNEY trial which demonstrated the benefits of empagliflozin in patients with chronic kidney disease. He was the clinical trial unit lead for the RECOVERY trial during the covid pandemic. The RECOVERY trial was the world’s largest trial of therapy for covid and has found four treatments improve the prognosis of hospitalised patients and several more do not. Richard’s work focuses on streamlining clinical trials and making them part of the standard of care so that people with or at risk of a wide variety of conditions can benefit from participation and their results.